Clinical trials: Anaplastic Astrocytomas
Brain Tumor, Astrocytoma
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Background: Zotiraciclib (TG02) is an investigational drug that penetrates the blood-brain barrier and might treat brain tumors. Temozolomide (TMZ) is a drug used to treat brain tumors.
- Conditions
- Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma
- Trial name
- NCT02942264
- Testing
- Zotiraciclib (TG02), Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Cerebral Edema
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
RATIONALE: Giving the herb Boswellia serrata after surgery and radiation therapy may slow the growth of any remaining tumor cells.
- Trial name
- NCT00243022
- Testing
- Boswellia serrata extract, cyanocobalamin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ali Altunkaya
Glioblastoma Multiforme, Anaplastic Astrocytoma
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory central nervous system tumors for which there are no curative options.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Malignant Brain Tumor, High Grade Glioma
- Trial name
- NCT02885324
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Indiana University
Anaplastic Astrocytoma
Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
RATIONALE: Current therapies for adults with anaplastic astrocytomas that have not responded to standard therapy provide very limited benefit to the patient.
- Trial name
- AA (NCT00003470)
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Burzynski Research Institute
Brain Tumor
PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors
The purpose of this study is to determine the antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors.
- Trial name
- NCT00763750
- Testing
- PPX +TMZ+XRT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- howard safran
Glioma, High Grade Astrocytoma
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present…
- Conditions
- Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01081223
- Testing
- Cancer vaccine plus immune adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- TVAX Biomedical
Glioblastoma, Gliosarcoma
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Primary objective: To estimate 6-month progression free survival probability of pts w recurrent malignant gliomas treated w erlotinib + bevacizumab.
- Trial name
- NCT00671970
- Testing
- Bevacizumab and Erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Anaplastic Astrocytoma, Central Nervous System Neoplasm
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
This phase II trial is studying how well giving radiation therapy together with temozolomide and lomustine works in treating young patients with newly diagnosed gliomas.
- Conditions
- Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma, Gliosarcoma
- Trial name
- NCT00100802
- Testing
- Laboratory Biomarker Analysis, Lomustine, Radiation Therapy
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Children's Oncology Group
Glioblastoma, Gliosarcoma
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Background: In order to survive, brain tumors must have a network of blood vessels to supply it with oxygen and nutrients. The tumors produce substances that enable new blood vessels to form.
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00667394
- Testing
- Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simplex Virus-1 in patients who would not be eligible for surgical resection of recurrent glioma To determine the safety and…
- Conditions
- Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
- Trial name
- M032-HSV-1 (NCT02062827)
- Testing
- M032 (NSC 733972)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Alabama at Birmingham
Brain and Central Nervous System Tumors
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00337207
- Testing
- bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Northwestern University
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme/Anaplastic Astrocytoma
Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00841555
- Testing
- temozolomide, Hypofractionated radiation therapy, Intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Brain Cancer, Glioblastoma Multiforme
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I Objectives: -To determine the maximum tolerated dose (MTD) of vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide in adult patients with recurrent glioblastoma multiforme (GBM) and anaplastic gliomas.
- Trial name
- NCT01110876
- Testing
- Vorinostat, Erlotinib, Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking some of the blood flow to the tumor.
- Trial name
- NCT00553150
- Testing
- everolimus, temozolomide, radiation
- Where
- 178 sites in United States
- Volunteers
- 122 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioma, Anaplastic Astrocytoma
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches.
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT03072134
- Testing
- Neural stem cells loaded with an oncolytic adenovirus
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide.
- Trial name
- NCT01026493
- Testing
- temozolomide 60 mg x 21 days, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days
- Where
- 17 sites in United States
- Volunteers
- 257 people
- Sponsor
- Radiation Therapy Oncology Group
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide, carmustine, and lomustine, use different ways to stop tumor cells from dividing so they stop growing or…
- Trial name
- NCT00004259
- Testing
- BCNU 80mg/m2, TMZ 200mg/m2, radiation therapy
- Where
- 92 sites in United States
- Volunteers
- 230 people
- Sponsor
- Radiation Therapy Oncology Group
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Bevacizumab may reduce CNS side effects caused by radiation therapy. This randomized phase II trial is studying how well bevacizumab works in reducing CNS side effects in patients who have undergone radiation therapy to the brain…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT00492089
- Testing
- bevacizumab, magnetic resonance imaging, quality-of-life assessment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)